Skip to main content
Top
Published in: Rheumatology International 10/2019

01-10-2019 | Systemic Lupus Erythematosus | Cohort Studies

Mental disorders in systemic lupus erythematosus: a cohort study

Authors: Heidi Fernandez, Andrea Cevallos, Ruth Jimbo Sotomayor, Fernando Naranjo-Saltos, Diego Mera Orces, Efrain Basantes

Published in: Rheumatology International | Issue 10/2019

Login to get access

Abstract

Currently, the evaluation of mental disorders in patients with Systemic lupus erythematosus (SLE) is essential in the management of the illness because of their impact in morbimortality. The main purpose of this study was to determine the prevalence of mental disorders in a group of patients with SLE in a tertiary referral hospital in Quito-Ecuador. The main diffuse central nervous system psychiatric syndromes in SLE (psychosis, anxiety and mood disorders) and cognitive dysfunction were evaluated with the MINI International Neuropsychiatric Interview and the Montreal scale, respectively. This was a descriptive, cross-sectional study which included patients 15 years and older diagnosed with SLE in a tertiary referral hospital in Quito, Ecuador. 85 patients diagnosed with SLE attending the internal medicine outpatient clinic during October 2017–May 2018 were included. A bivariate analysis of possible associations between these mental disorders with corticosteroid use, antiphospholipid syndrome (APS), and quality of life was also studied. Eighty-five patients, with an average age of 34.12 ± 11.5 years were included, of which 94% were females. 71% of participants (60 patients) had at least one mental disorder evaluated in this study. The most frequent was cognitive impairment (n = 43, 51%) followed by anxiety disorders (n = 35, 41%), mood disorders (n = 34, 40%) and psychosis (n = 1; 1%). 38% presented mild cognitive impairment and 13% had moderate cognitive impairment. Memory and visuospatial/executive function were the most affected domains in the cognitive assessment. 38% of participants were previously diagnosed with antiphospholipid syndrome, of which 78% had a mental disorder (OR = 1.83, p = 0.2). Most patients (n = 84; 99%) were treated with corticosteroids, of these, 59 patients presented a mental disorder (OR = 0.9, p = 0.8). Associations with APS or corticosteroid use were not statistically significant. However, the multivariate regression suggests an association between presence of mental disease and quality of life. There were statistically significant alterations in anxiety/depression and pain. There is a high prevalence of neuropsychiatric syndromes in this cohort of patients. Almost ¾ of our cohort had at least one mental disorder, the most common was cognitive impairment.
Literature
5.
go back to reference Dorman G, Micelli M, Cosentino V, Ottone L, Nuñez MR, Mangone C, Genovese O (2017) Disfunción cognitiva en lupus eritematoso sistémico y su asociación con actividad y daño. Medicina (Buenos Aires) 2017(77):257–260 Dorman G, Micelli M, Cosentino V, Ottone L, Nuñez MR, Mangone C, Genovese O (2017) Disfunción cognitiva en lupus eritematoso sistémico y su asociación con actividad y daño. Medicina (Buenos Aires) 2017(77):257–260
15.
go back to reference Wekking EM (1993) Psychiatric Symptoms in Systemic Lupus Erythematosus: an Update. Psychosom Med 55(2):219–228CrossRefPubMed Wekking EM (1993) Psychiatric Symptoms in Systemic Lupus Erythematosus: an Update. Psychosom Med 55(2):219–228CrossRefPubMed
22.
Metadata
Title
Mental disorders in systemic lupus erythematosus: a cohort study
Authors
Heidi Fernandez
Andrea Cevallos
Ruth Jimbo Sotomayor
Fernando Naranjo-Saltos
Diego Mera Orces
Efrain Basantes
Publication date
01-10-2019
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 10/2019
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-019-04423-4

Other articles of this Issue 10/2019

Rheumatology International 10/2019 Go to the issue